Siglecs as Immune Cell Checkpoints in Disease

Sialic acid-binding immunoglobulin-type lectins (Siglecs) are expressed on the majority of white blood cells of the immune system and play critical roles in immune cell signaling. Through recognition of sialic acid-containing glycans as ligands, they help the immune system distinguish between self a...

Full description

Saved in:
Bibliographic Details
Published inAnnual review of immunology Vol. 38; p. 365
Main Authors Duan, Shiteng, Paulson, James C
Format Journal Article
LanguageEnglish
Published United States 26.04.2020
Subjects
B cell
Siglec
Alzheimer disease
T cell
cancer
CD22
CD33
lymphocyte
Online AccessGet more information

Cover

More Information
Summary:Sialic acid-binding immunoglobulin-type lectins (Siglecs) are expressed on the majority of white blood cells of the immune system and play critical roles in immune cell signaling. Through recognition of sialic acid-containing glycans as ligands, they help the immune system distinguish between self and nonself. Because of their restricted cell type expression and roles as checkpoints in immune cell responses in human diseases such as cancer, asthma, allergy, neurodegeneration, and autoimmune diseases they have gained attention as targets for therapeutic interventions. In this review we describe the Siglec family, its roles in regulation of immune cell signaling, current efforts to define its roles in disease processes, and approaches to target Siglecs for treatment of human disease.
ISSN:1545-3278
DOI:10.1146/annurev-immunol-102419-035900